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pattern glomerulonephritisSummary Allogeneic hematopoietic stem cell transplantation (HSCT)–related membranous glomer-
ulonephritis (MGN) is poorly understood. A total of 830 patients who underwent HSCT at Toranomon
Hospital from 2000 to 2012 were evaluated retrospectively, including 621 patients receiving umbilical
cord blood transplantation (UCBT) and 208 patients receiving unrelated bone marrow transplantation.
MGN was diagnosed in 5 patients after UCBT (versus none after bone marrow transplantation) and
occurred concomitantly with chronic graft-versus-host disease after cessation of immunosuppression.
Light microscopy did not show any definite spikes or bubbling of the glomerular basement membrane
(GBM) in all 5 patients. In 1 patient (case 5), endocapillary proliferative lesions with fibrin-like deposits
were noted in addition to MGN findings. Immunofluorescence demonstrated granular deposits of
immunoglobulin G (IgG; IgG1 and IgG4) along the GBM with negativity for C3, C4, and C1q in 4
patients (cases 1-4), whereas case 5 showed positivity for IgG (IgG1, IgG2, IgG3, and IgG4) as well as
for C3, C4, and C1q. Electron microscopy revealed electron-dense deposits in the subepithelial space of
the GBM in cases 1-4. In case 5, electron-dense deposits were present in the mesangium and the
subendothelial space of the GBM, as well as in the subepithelial space. After treatment with
immunosuppressants (prednisolone and/or cyclosporin) or angiotensin-converting enzyme inhibitors,
complete remission with disappearance of proteinuria was achieved 12.2 months in all 5 patients, but☆ Competing interest: All authors report no conflicts of interest.
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188 R. Hiramatsu et al.nephrotic-range proteinuria relapsed in 2 patients during follow-up. Serum anti-PLA2R autoantibody
was negative in 3 patients. HSCT-related MGN only occurred after UCBT. We believe that there were 2
morphologic patterns: early MGN and membranoproliferative pattern glomerulonephritis.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Allogeneic hematopoietic stem cell transplantation
(HSCT) is a common treatment of a variety of hematopoietic
malignancies. Chronic kidney disease develops in 15% to
20% of recipients at several months after HSCT and is
considered due to chronic calcineurin inhibitor nephrotox-
icity, HSCT-associated thrombotic microangiopathy
(TMA), and glomerular diseases including membranous
glomerulonephritis (MGN), minimal change disease
(MCD), membranoproliferative glomerulonephritis, and
focal segmental glomerulosclerosis [1]. Brukamp et al [2]
found that MGN accounted for almost two-thirds of
nephrotic syndrome after HSCT, followed byMCD in nearly
one quarter of patients. MGN occurs in synchronization with
manifestation of chronic graft-versus-host disease (CGVHD)
such as skin lesions shortly after the cessation of immunosup-
pressive therapy, soMGN after HSCT is considered secondary
to CGVHD.
On the other hand, idiopathic MGN is the main cause of
nephrotic syndrome in adults and is characterized by
accumulation of immune complexes in the glomerular
basement membrane (GBM). The immunoglobulin (Ig) G
deposits in the glomeruli are predominantly composed of
IgG4. Recently, the M-type phospholipase A2 receptor
(PLA2R) in podocytes was proposed as the major target
antigen involved in adult idiopathic MGN [3,4].
Detailed evaluation of post-HSCTMGN by a combination
of 3 microscopic techniques (light microscopy [LM], electron
microscopy [EM], and immunofluorescence [IF] studies
including IgG subclass analysis) has not been done before.
Accordingly, we performed a detailed clinicopathological
investigation of 5 patients with post-HSCT MGN. We also
evaluated the association with anti-PLA2R autoantibody in
3 patients.2. Materials and methods
2.1. Patient selection
At Toranomon Hospital, HSCT using umbilical cord
blood (UCBT) was performed in 621 patients from 2000 to
2012, while HSCT using unrelated bone marrow (BMT) was
done in 208 patients. Renal biopsy was performed for
evaluation of renal pathology in 20 patients with proteinuriaat least 0.3 g daily. These patients were divided into group 1
(11 patients after UCBT) and group 2 (9 patients after BMT).
In group 1, the renal histology was MGN in 5 patients, acute
tubular necrosis in 2, diabetic nephropathy in 2, TMA in 1,
and nephrosclerosis in 1. In group 2, renal histology was
acute tubular necrosis in 6 patients, TMA in 2, and MCD in
1.
The 5 patients with MGN from group 1 were analyzed
retrospectively. None of them had any of the common causes
of secondary MGN, such as malignancy, autoimmune disease
such as lupus erythematosus, or hepatitis C and B virus
infection.
This study was approved by the local institutional review
board, and the patients signed a full informed consent.
2.2. Histologic evaluation
Renal biopsy specimens were processed for LM, IF
microscopy, and EM according to the previous method [5].
IFs were performed for IgG, IgA, IgM, and IgG subclasses
(IgG1-IgG4), as well as antibodies for complement compo-
nent (C)1q, C3, and C4.2.3. Laboratory tests
Before renal biopsy, blood and urine samples were
collected from all patients. Laboratory tests were performed
to measure the hemoglobin, white blood cell count, platelet
count, serum creatinine, IgG, IgA, IgM, cryoglobulin,
antinuclear antibody (including anti–double-stranded
DNA antibody and anti–U1-nuclear ribonucleoprotein
antibody), 50% hemolytic complement (reference range,
32-47 U/mL), and the estimated glomerular filtration rate (in
mL/min per 1.73 m2). Serum hepatitis C virus antibody was
evaluated by enzyme-linked immunosorbent assay (Abbott
Diagnostics, Maidenhead, UK), and hepatitis B virus
antibody was detected with another commercially available
enzyme-linked immunosorbent assay kit. Assessment of
24-hour urinary protein excretion was performed, and the
urine sediment was examined, including the number of
erythrocytes per high-power field. Serum monoclonal
protein and urinary Bence-Jones protein were analyzed by
protein electrophoresis and/or immunofixation electropho-
resis. Serum anti-PLA2R autoantibody was measured in 3 of
the 5 patients (patients 1, 4, and 5) according to the
previously reported method [4].
Fig. 1 Renal biopsy specimens of case 3, which are representative of cases 1 to 4. A, At the first biopsy, LM did not show any definite spike
formation or bubbling of theGBM.B,At the second biopsy, LMshowed definite spikes and bubbling of theGBM.C, Inset shows amagnified view
of panel B.D, IF revealed granular deposition of IgG along theGBM.E,At the first biopsy, EMshowedEDDs (arrows) in the subepithelial space of
the GBM. These subepithelial deposits were stage 1 without spike-like protrusions arising from the basement membrane. F, At the second biopsy,
EM showed a mixture of stage 1 to III subepithelial deposits without (new, small arrow) or with (old, large arrow) spikes.
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Statistical analysis was performed using the χ
2
test.
Quantitative values were expressed as the mean ± SD, and
differences were compared by Wilcoxon rank-sum test. A
probability (P) value less than .05 was considered to indicate
statistical significance. The SPSS software package
(SPSS 11.0 for Windows; SPSS, Chicago, IL) was used for
all analyses.3. Results
3.1. Renal first biopsy findings
LM did not show any definite spike formation or
bubbling (Fig. 1A) of the GBM in all 5 patients, but
endocapillary proliferative lesions with fibrin-like deposits
were noted in glomeruli from case 5 (Fig. 2A-C). IF
demonstrated granular deposition of IgG along the GBM in
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B
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D
E
Fig. 2 The renal biopsy specimen of case 5. A, Endocapillary proliferative lesions (Periodic acid–Schiff [PAS] stain). B, Endocapillary
proliferative lesions (small arrows) in the inset of panelA (PAS stain). C, Fibrin-like deposits (large arrow)were noted in 2 of 19 glomeruli (periodic
acid–silvermethenamine andMasson trichrome). D, IF showed IgG staining along the GBMand in themesangial region. Stainingwas positive for
IgG1, IgG2, IgG3, and IgG4,whereasC3,C4, andC1qwere also positive. E, EDDswere seen in themesangium and the subendothelial space of the
GBM (white arrows), as well as in the subepithelial space (black arrows).
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191Membranous glomerulonephritis after HSCTall 5 patients (Fig. 1D), whereas IgG was also seen in the
mesangial region in case 5 (Fig. 2D). In cases 1 to 4, IgG1
and IgG4 were equally positive. In case 5, there was
positivity of IgG1, IgG2, IgG3, and IgG4 (Fig. 2D).
Although C3, C4, and C1q were negative in cases 1 to 4
(Fig. 1D), these complement components were positive in
case 5 (Fig. 2D). EM showed subepithelial electron-dense
deposits (EDDs) in the GBM (Fig. 1E) of all 5 cases. In
case 5, EDDs were also mainly located in the subepithelial
space of the GBM, but were partially in the mesangial
region and the subendothelial space (Fig. 2E). The
subepithelial EDDs were stage 1 without spike-like
protrusions arising from the basement membrane. EDDs
were very small and segmental in cases 1, 2, and 4,
whereas EDDs were larger and more extensive in cases 3
and 5. There were 2 morphologic patterns: early MGN (in
cases 1-4) and membranoproliferative pattern glomerulo-
nephritis (in case 5; Table 1).
3.2. Renal second biopsy findings
In cases 3 and 4, a second renal biopsy was performed
after recurrence of nephrotic-range proteinuria. LM re-
vealed definite spikes or bubbling of the GBM (Fig. 1B and
C). EM demonstrated a mixture of stage 1 to stage III
subepithelial deposits without (new) or with (old) spike
(Fig. 1F).
3.3. Patient characteristics
The primary malignant disease that was the indication for
HSCT was different in each patient, being non–Hodgkin
lymphoma, myelodysplastic syndrome, acute lymphoblastic
leukemia, plasmacytic lymphoma, and diffuse large B-cell
lymphoma. The conditioning regimen (for the purpose of
eradicating the malignancy prior to HSCT and suppressing
immune reactions) was a combination of total bone irradiation
(n = 4, 2-8 Gy) and chemotherapy with fludarabine (n = 5) and
busulfan (n = 2) or melphalan (n = 3). CGVHD occurred in the
skin, eye, liver, bowel, and nervous system. The time from
HSCT to the onset of CGVHDwas 7 to 19months, whereas the
time fromCGVHDonset to the occurrence ofMGNwas 2 to 15
months (Table 2).
3.4. Laboratory data at the onset of MGN
Serum creatinine was 0.8 to 1.3 mg/dL, estimated
glomerular filtration rate was 45 to 89 mL/min per 1.73
m2, and urinary protein was 5.93 to 13.0 g/d (mean, 8.4 g/d).
Fifty percent hemolytic complement was normal with 42 to
51 U/mL in 3 patients, but was not measured in the other 2
patients. Serum anti-PLA2R autoantibody was negative in 3
patients, but was not tested in the other 2 patients (Table 3).
Ultrasonography did not show any finding suggesting renal
vein thrombosis on 5 patients.3.5. Treatment and long-term outcomeThe mean observation period after the onset of MN was
92.4 months (range, 38-144 months). Initial treatment of
MGN was only an angiotensin-converting enzyme inhibitor
in 1 patient, whereas the other 4 patients received
prednisolone (PSL; 0.6-0.8 mg/kg/d) and/or cyclosporin
(CyA; 50-75 mg/d). All patients achieved complete remis-
sion (CR) with disappearance of proteinuria after treatment
for a mean of 12.2 months (5-24 months). However,
nephrotic-range proteinuria recurred in 2 patients (cases 3
and 4) during follow-up. Cases 3 and 4 also had coexisting
extrarenal symptoms of GVHD (bronchiolitis or skin lesion).
Treatment was started with PSL (35 mg daily) and CyA (50
mg daily), and proteinuria subsided after 2 months. In case 4,
there was also recurrence of nephrotic-range proteinuria (9.8
g daily). Because proteinuria persisted despite administration
of PSL (50 mg daily) and CyA (50 mg daily), hemodialysis
was started for end-stage renal failure at 73 months after
HSCT (Table 4).4. Discussion
When Otani et al [6] reviewed previous reports, they
found that HSCT-related MGN has a pattern resembling
secondary MGN, because immune complex deposits are
mainly localized in the subepithelium of the GBM, and
mesangial deposits are also found in some patients. Similar
symptoms and renal histologic changes have been reported
in a murine model of GVHD. Chang et al [7] reported 3
cases of HSCT-related MGN consistent with the early stage
of MGN or with atypical MGN. In addition, Chan et al
reported 4 cases of MGN. The glomerular capillary walls
displayed varying stages of remodeling. Two patients were
diagnosed as having atypical MGN showing a few
mesangial EDDs [8]. Furthermore, Reddy et al [9] reported
5 cases of HSCT-relatedMGN showing a mixture of stages 1 to
3 with diffuse thickening of the GBM and that deposits exist on
both subepithelial and intramembranous sites. Terrier et al [10]
also reported 5MGN patients. Renal biopsy showed early stage
of MGN. IgG1 was positive in 5 patients. EM findings were not
shown.
The mechanism underlying the development of MGN
after HSCT remains unclear. Many patients with MGN have
active CGVHD at the diagnosis of MGN. Close relation
between CGVHD and MGN is suggested [10]. GVHD is
primarily a T-cell–mediated disease, in which donor T cells
recognize major histocompatibility complex mismatch, as
well as targeting other host antigens [11]. A recent report
suggested that B cells also contribute to GVHD thorough
both antibody-dependent and antibody-independent
mechanisms [12]. In a murine model of CGVHD after
myeloablative transplantation, there have been reports of
Table 1 Renal first biopsy findings
Patient
1 2 3 4 5
LM
Spike formation on GBM (−) (−) (−) (−) (−)
Endocapillary proliferative lesion (−) (−) (−) (−) (+)
IF
IgG GBM(+)Mes(−) GBM(+)Mes(−) GBM(+)Mes(−) GBM(+)Mes(−) GBM(+)Mes(+)
IgA (−) (−) (−) (−) (−)
IgM (−) (−) (−) (−) (+)
IgG1 (+) (+) (+) (+) (+)
IgG2 (−) (−) (−) (−) (+)
IgG3 (−) (−) (−) (−) (+)
IgG4 (+) (+) (+) (+) (+)
C3 (−) (−) (−) (−) (+)
C4 (−) (−) (−) (−) (+)
C1q (−) (−) (−) (−) (+)
EM
EDD Subepi(+) Subepi(+) Subepi(+) Subepi(+) Subepi(+)Mes(+)
Size and amount of EDD Small and seg Small and seg Large and many Small and seg Large and many
Abbreviations: LM, light microscopy; GBM, along the glomerular basement membrane; IF, immunofluorescence; Mes, in the mesangial space; IgG, IgA,
IgM, immunoglobulins G, A, and M; EM electron microscopy; EDD, electron dense deposits; Subepi, in the subepithelial spaces; seg, segmental.
Table 2 Patient characteristics
Patient
1 2 3 4 5
Age (y)/sex 48/M 50/M 35/M 60/M 48/F
Primary disease NHL MDS ALL Plasmatic lymphoma DLBCL
Chemotherapy as conditioning regimen Flu/Bu Flu/Bu Flu/Mel Flu/Mel Flu/Mel
TBI as conditioning regimen (Gy) 2 4 8 None 2
IS CyA TAC/PSL TAC/PSL CyA TAC/PSL
Clinical manifestation of CGVHD Skin Eyes, skin Skin, liver, lung, intestine Skin, nerve Skin, eyes
Duration from HSCT to CGVHD (mo) 9 19 9 7 7
Duration from CGVHD to MGN (mo) 6 21 9 2 25
Duration from HSCT to MGN (mo) 15 40 18 9 32
Abbreviations: M, male; F, female; NHL, non–Hodgkin lymphoma; MDS, marrow dysplasia syndrome; ALL, acute lymphoblastic leukemia; DLBCL, diffuse
large B-cell lymphoma; Flu, fludarabine; Bu, busulfan;Mel, melphalan; TBI, total bone irradiation; IS, immunosuppressant; CyA, cyclosporin; TAC, tacrolimus;
PSL, prednisolone; CGVHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; MGN, membranous glomerulonephritis.
192 R. Hiramatsu et al.antibodies against nephrin causing severe immune complex
glomerulonephritis [13,14]. CGVHD in humans sometimes
shares clinical manifestations with various autoimmune
diseases [15].
Huang et al [16] reported anti-PLA2R autoantibodies on 5
patients with post–allo-HSCT MN. Anti-PLA2R autoanti-
bodies were negative in 4 patients, whereas serum from 1
patient was reactive with PLA2R.
Chan et al [8] reported the clinical courses of 4 patients
with post-HSCT MGN. Three of the 4 patients were
followed up for a mean period of 29.3 months and were
treated with PSL, angiotensin-converting enzyme inhibitor,
mycophenolate mofetil, or CyA. Two patients achieved CR,
but 1 patient developed renal impairment. Reddy et al [9]reported that all 5 of their patients showed improvement of
proteinuria, whereas the 2 patients receiving initial treatment
with rituximab had an excellent response. Terrier et al [10]
reported that 75% of their patients achieved partial or CR with
PSL and CyA therapy. Regarding the long-term outcome,
Kemper et al [17] reported survival with continuous remission
of proteinuria in patients with post-HSCT MGN at 96 months
after ceasing treatment ofMGN, and Cupelli et al [18] reported
the same outcome after 60 months.
Because isolated staining for IgG4with positive staining for
C3 and positivity for anti-PLA2R autoantibody are considered
to be the characteristics of idiopathicMGN [3], our first 4 cases
may be consistent with secondary MGN because they showed
predominant IgG1 and IgG4 staining with negative C3
Table 3 Laboratory data at onset of MGN
Patient
1 2 3 4 5
Total protein (g/dL) 4.9 4.8 4.2 5.6 4.2
Serum albumin (g/dL) 3.1 2.5 1.6 2.7 1.4
Serum Cre (mg/dL) 0.8 1.3 0.8 1.3 1
eGFR (mL/min per 1.73 m2) 82 47 89 45 47
White blood cell (×104/μL) 6.8 5.3 13.8 13.5 6.1
Hemoglobin (g/dL) 15.3 14.5 14.4 11 14.7
Platelet count (×104/μL) 20 20.7 19.4 17 23.1
IgG (mg/dL) 616 391 487 873 473
IgA (mg/dL) 121 101 122 244 67
IgM (mg/dL) 85 80 85 108 56
CH50 (U/mL) ND 43 ND 42 51
Cryoglobulin Negative Negative Negative Negative Negative
Antinuclear antibody Negative Negative Negative Negative Negative
Urinary protein (g/d) 5.9 9.5 6.5 7.1 13
Urinary sediment of erythrocyte (/HPF) b1 1-5 1-5 b1 6-10
Serum anti-PLA2R autoantibody ND Negative Negative ND Negative
Serum monoclonal protein Negative Negative Negative Negative Negative
Urinary Bence-Jones protein Negative Negative Negative Negative Negative
Abbreviations: MGN, membranous glomerulonephritis; Cre, creatinine; eGFR, estimated glomerular filtration rate; IgG, IgA, IgM, immunoglobulins G, A,
and M; CH50, 50% hemolytic complement; ND, not done; HPF, high-power field.
Table 4 Treatment and long-term outcome
Patient
1 2 3 4 5
Observation time after onset of MGN (mo) 116 96 68 144 38
Treatment of MGN ACEi PSL 20 mg+ PSL 30 mg PSL 30 mg PSL 50 mg
CyA 75 mg CyA 50 mg CyA 75 mg
Duration time until first CR was achieved (mo) 21 24 5 6 5
Duration time from CR of MGN to relapse of MGN (mo) 43 27
Abbreviations: MGN, membranous glomerulonephritis; ACEi, angiotensin-converting enzyme inhibitor; PSL, prednisolone; CyA, cyclosporin; CR,
complete remission.
193Membranous glomerulonephritis after HSCTstaining. On the other hand, our last case indicates that other
types of HSCT-related nephropathy with membranoprolifera-
tive glomerulonephritis–like lesions can also occur.
In conclusion, we found that HSCT-related MGN is
developed only after using UCBT, but is not developed
after using unrelated BMT. Although previous reports did
not differentiate the 2 methods, the presence of HLA
antibodies against the UCB units may be a causative factor
of MGN.
The pathogenesis of close relation between UCBT and
MGN will be solved. There were 2 morphologic patterns:
early MGN and membranoproliferative pattern glomerulo-
nephritis. Because PLA2R in 3 cases was all negative, this
nephropathy may be consistent with secondary MGN. MGN
was developed 2 to 15 months after CGVHD onset on 5
cases, and in 2 cases with recurrence of this nephropathy,
extrarenal symptoms of GVHD coexisted. This will show a
close relation considered between CGVHD and MGN.Acknowledgments
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